A detailed history of Hrt Financial LP transactions in Incyte Corp stock. As of the latest transaction made, Hrt Financial LP holds 328,069 shares of INCY stock, worth $23.5 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
328,069
Previous 473,258 30.68%
Holding current value
$23.5 Million
Previous $28.7 Million 24.41%
% of portfolio
0.12%
Previous 0.17%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$57.33 - $68.61 $8.32 Million - $9.96 Million
-145,189 Reduced 30.68%
328,069 $21.7 Million
Q2 2024

Aug 12, 2024

BUY
$51.18 - $63.75 $14.8 Million - $18.5 Million
289,581 Added 157.66%
473,258 $28.7 Million
Q1 2024

May 13, 2024

BUY
$56.55 - $66.59 $63,336 - $74,580
1,120 Added 0.61%
183,677 $10.5 Million
Q4 2023

Feb 09, 2024

BUY
$52.16 - $64.19 $4.03 Million - $4.96 Million
77,256 Added 73.37%
182,557 $11.5 Million
Q3 2023

Nov 13, 2023

SELL
$57.77 - $65.93 $1.14 Million - $1.3 Million
-19,701 Reduced 15.76%
105,301 $6.08 Million
Q2 2023

Aug 11, 2023

BUY
$60.95 - $75.51 $7.62 Million - $9.44 Million
125,002 New
125,002 $7.78 Million
Q4 2022

Feb 10, 2023

BUY
$67.18 - $84.11 $4.85 Million - $6.08 Million
72,231 New
72,231 $5.8 Million
Q2 2022

Aug 12, 2022

BUY
$66.18 - $83.18 $6.11 Million - $7.68 Million
92,347 New
92,347 $7.02 Million
Q1 2022

May 16, 2022

SELL
$66.02 - $79.71 $23 Million - $27.8 Million
-348,268 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$63.34 - $74.11 $22.1 Million - $25.8 Million
348,268 New
348,268 $25.6 Million
Q3 2021

Nov 15, 2021

SELL
$68.67 - $84.02 $4.08 Million - $5 Million
-59,454 Closed
0 $0
Q2 2021

Aug 16, 2021

BUY
$79.87 - $87.53 $4.75 Million - $5.2 Million
59,454 New
59,454 $5 Million

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Hrt Financial LP Portfolio

Follow Hrt Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.